Fighting the heart failure Pandemic

Welcome to CardiNor

Latest news from CardiNor

December 2023:
Oslo, December 6th, 2023 – CardiNor AS appoints Thomas B. Grünfeld as new CEO

CardiNor AS has appointed Thomas B. Grünfeld, MD, MPH, as new Chief Executive Officer. Thomas will replace Dag Christiansen who will continue working for CardiNor in a new role as Chief Operating Officer.

CardiNor is at a pivot stage of its development and is strengthening the leadership team to enable more focus on the clinical development and partnerships going forward.

Thomas brings with him experience from start-up MedTech companies both as CEO and board member, most recently from Labrida AS and Observe Medical AS, and has both clinical expertise and other relevant competence. He also brings in 30 years of experience from finance and business development from McKinsey & Co, Kistefos and Sarsia Life Science Fund.

Bjørn Fuglaas, Chairman of the board, states; I am very pleased that Thomas is strengthening the team, and he brings with him crucial competence at this stage of CardiNor’s development.

Press release – CardiNor AS appoints Thomas B. Grünfeld as new CEO

August 2023:
New publication – secretoneurin provide prognostic information in patients with chronic, stable HF

Secretoneurin (SN) data from the multicenter study GISSI Heart Failure Trial was published in Clinical Biochemistry, volume 118, August 2023.

The study was performed using the CE-marked CardiNor Secretoneurin ELISA Assay.

Individual patients with chronic heart failure (HF) have very different prognosis, also within subgroups classified according to etiology and left ventricular ejection fraction (LVEF). Circulating protein biomarkers have the potential to identify vulnerable patients that could benefit from special follow-up and uptitration of guideline-directed medical therapy. As B-type natriuretic peptide (BNP)-guided therapy has not demonstrated clear benefit over symptom-based management in major randomized-controlled trial, there is a need to identify additional prognostic biomarkers. Hence, biomarkers that provide incremental prognostic information to BNP, and preferably across the spectrum of LVEF, may prove important for future personalized management strategies in HF patients.

Circulating SN concentrations have been found to provide prognostic information in patients with acute heart failure. In this study plasma SN concentrations were measured at randomisation (n = 1224) and after 3 months (n = 1103) in patients with chronic, stable heart failure from the GISSI-HF study, and the aim was to assess whether SN would improve prognostication also in patients with chronic heart failure.

The authors H. Røsjø, J. Meessen, A. H. Ottesen, R. Latini and T. Omland, on behalf of the GISSI-HF Investigators highlighted that

  • SN concentrations separate stable heart failure patients with a poor and favorable prognosis
  • SN concentrations were not different between patients with Left Ventricle Ejection Fraction (LVEF) <50% and LVEF ≥50%
  • SN concentrations provided additional prognostic information to established risk indices and biomarkers in patients with stable heart failure.

The article is free, very useful and can be downloaded here:

CardiNor Contact Information


Gaustadalléen 21,
0349 Oslo, Norway


+47 922 54 855